To analyze the performance of the Prostate Health Index(phi)and its derivatives for predicting Gleason score(GS)upgrading between prostate biopsy and radical prostatectomy(RP)in the Chinese population,an observational...To analyze the performance of the Prostate Health Index(phi)and its derivatives for predicting Gleason score(GS)upgrading between prostate biopsy and radical prostatectomy(RP)in the Chinese population,an observational,prospective RP cohort consisting of 351 patients from two medical centers was established from January 2017 to September 2020.Pathological reclassification was determined by the Gleason Grade Group(GG).The area under the receiver operating characteristic curve(AUC)and logistic regression(LR)models were used to evaluate the predictive performance of predictors.In clinically low-risk patients with biopsy GG≤2,phi(odds ratio[OR]=1.80,95%confidence interval[95%CI]:1.14-2.82,P=0.01)and its derivative phi density(PHID;OR=2.34,95%CI:1.30-4.20,P=0.005)were significantly associated with upgrading to GG≥3 after RP,and the results were confirmed by multivariable analysis.Similar results were observed in patients with biopsy GG of 1 for the prediction of upgrading to RP GG≥2.Compared to the base model(AUC=0.59),addition of the phi or PHID could provide additional predictive value for GS upgrading in low-risk patients(AUC=0.69 and 0.71,respectively,both P<0.05).In conclusion,phi and PHID could predict GS upgrading after RP in clinically low-risk patients.展开更多
Eastern Cooperative Oncology Group(ECOG)performance status and Gleason score are commonly investigated factors for overall survival(OS)in men with castration-resistant prostate cancer(CRPC).However,there is a lack of ...Eastern Cooperative Oncology Group(ECOG)performance status and Gleason score are commonly investigated factors for overall survival(OS)in men with castration-resistant prostate cancer(CRPC).However,there is a lack of consistency regarding their prognostic or predictive value for OS.Therefore,we performed this meta-analysis to assess the associations of ECOG performance status and Gleason score with OS in CRPC patients and compare the two markers in patients under different treatment regimens or with different chemotherapy histories.A systematic literature review of monotherapy studies in CRPC patients was conducted in the PubMed database until May 2019.The data from 8247 patients in 34 studies,including clinical trials and real-world data,were included in our meta-analysis.Of these,twenty studies reported multivariate results and were included in our main analysis.CRPC patients with higher ECOG performance statuses(≥2)had a significantly increased mortality risk than those with lower ECOG performance statuses(<2),hazard ratio(HR):2.10,95%confidence interval(CI):1.68-2.62,and P<0.001.The synthesized HR of OS stratified by Gleason score was 1.01,with a 95%CI of 0.62-1.67(Gleason score≥8 vs<8).Subgroup analysis showed that there was no significant difference in pooled HRs for patients administered taxane chemotherapy(docetaxel and cabazitaxel)and androgen-targeting therapy(abiraterone acetate and enzalutamide)or for patients with different chemotherapy histories.ECOG performance status was identified as a significant prognostic factor in CRPC patients,while Gleason score showed a weak prognostic value for OS based on the available data in our meta-analysis.展开更多
We aimed to compare Gleason score and tumor laterality between transrectal ultrasound-guided biopsy of the prostate （TRUSBX） and radical prostatectomy （RP）. Some factors that could cause a discrepancy in results b...We aimed to compare Gleason score and tumor laterality between transrectal ultrasound-guided biopsy of the prostate （TRUSBX） and radical prostatectomy （RP）. Some factors that could cause a discrepancy in results between these two procedures were also evaluated. Among the 318 cases reviewed, 191 cases were selected for inclusion in this comparative Study, We divided the patients into two groups using the Gleason score： an intermediate/high-grade group （≥7） and a low-grade group （〈6）. Exploratory analyses were conducted for comparisons between groups. We also performed comparisons between TRUSBX and RP for tumor laterality. TRUSBX overestimated 6% and underestimated 24% cases in comparison with RP for Gleason score, and overestimated 2.6% and underestimated 46% cases compared with RP for tumor laterality. Biopsy specimens were slightly smaller in TRUSBX cases with underestimated tumor laterality （P〈 0.05）, and no relationship between the biopsy specimen size and underestimated Gleason score in TRUSBX was found. Prostatic volume showed no statistical correlation with the likelihood of under or overestimation （P 〉 0.05）. Thus, our study showed that TRUSBX has a high likelihood of underestimating both the Gleason score and tumor laterality in prostate cancer （PCa）. The size of the fragment appears to be an important factor influencing the likelihood of laterality underestimation and Gleason score overestimation via TRUSBX. Due to the high likelihood of underestimation of the Gleason score and tumor laterality by 12-core prostate biopsy, we conclude that this type of biopsy should not be used alone to guide therapy in Pca.展开更多
目的研究前列腺癌磁共振扩散张量成像(DTI)参数表观扩散系数(ADC)与各向异性分数(FA)与其病理分级(Gleason评分)的关系,评价ADC值与FA值对于前列腺癌病理分级的诊断价值及评价前列腺癌危险度分级的诊断效能。方法采用3.0 T MR对70例经...目的研究前列腺癌磁共振扩散张量成像(DTI)参数表观扩散系数(ADC)与各向异性分数(FA)与其病理分级(Gleason评分)的关系,评价ADC值与FA值对于前列腺癌病理分级的诊断价值及评价前列腺癌危险度分级的诊断效能。方法采用3.0 T MR对70例经病理证实的前列腺癌患者行DTI检查,b值为0和800 s/mm2。测量前列腺癌的ADC值及FA值,根据病理结果将患者按Gleason评分系统分为高、中、低危三组:Gleason≥8分、Gleason=7分、Gleason≤6分。对三组数据进行单因素方差分析(one-way ANOVA),并进行组间两两比较。采用Pearson相关分析检验前列腺癌ADC值及FA值与Gleason评分的相关性。将前列腺癌Gleason评分≤7与Gleason评分≥8两组之间进行受试者工作特性(ROC)曲线分析,判断低中危组与高危组诊断界值。结果三组前列腺癌区平均ADC值分别为(0.96±0.10)×10-3mm2/s、(0.76±0.15)×10-3mm2/s和(0.62±0.12)×10-3mm2/s,FA值分别为0.39±0.06、0.31±0.09和0.22±0.06;三组ADC值、FA值组间差异均具有统计学意义(P<0.05);ADC值、FA值与Gleason评分之间均呈负相关(ADC值r=-0.768,P<0.05;FA值r=-0.662,P<0.05),两者均随Gleason评分的增高而减小。以ADC=0.68×10-3mm2/s为临界点,区分低中危组与高危组癌灶的诊断敏感性84.2%,特异性76.9%,准确性87.1%;以FA=0.24为临界点,区分低中危组与高危组癌灶的诊断敏感性79.5%,特异性75.8%,准确性78.4%。结论前列腺癌ADC值及FA值与病理分级(Gleason评分)之间呈负相关,具有预测癌灶恶性程度的潜力,有助于预测前列腺癌的恶性程度。展开更多
基金supported by grants from the National Natural Science Foundation of China(No.81772741 and No.81972645),Shanghai Jiao Tong University School of Medicine Gaofeng-Clinical Medicine Grant Support(No.20181701)Shanghai Municipal Human Resources and Social Security Bureau(No.2018052)to RNthe Clinical Research Project of Shanghai Health Commission(No.20214Y0511)to YSW.
文摘To analyze the performance of the Prostate Health Index(phi)and its derivatives for predicting Gleason score(GS)upgrading between prostate biopsy and radical prostatectomy(RP)in the Chinese population,an observational,prospective RP cohort consisting of 351 patients from two medical centers was established from January 2017 to September 2020.Pathological reclassification was determined by the Gleason Grade Group(GG).The area under the receiver operating characteristic curve(AUC)and logistic regression(LR)models were used to evaluate the predictive performance of predictors.In clinically low-risk patients with biopsy GG≤2,phi(odds ratio[OR]=1.80,95%confidence interval[95%CI]:1.14-2.82,P=0.01)and its derivative phi density(PHID;OR=2.34,95%CI:1.30-4.20,P=0.005)were significantly associated with upgrading to GG≥3 after RP,and the results were confirmed by multivariable analysis.Similar results were observed in patients with biopsy GG of 1 for the prediction of upgrading to RP GG≥2.Compared to the base model(AUC=0.59),addition of the phi or PHID could provide additional predictive value for GS upgrading in low-risk patients(AUC=0.69 and 0.71,respectively,both P<0.05).In conclusion,phi and PHID could predict GS upgrading after RP in clinically low-risk patients.
文摘Eastern Cooperative Oncology Group(ECOG)performance status and Gleason score are commonly investigated factors for overall survival(OS)in men with castration-resistant prostate cancer(CRPC).However,there is a lack of consistency regarding their prognostic or predictive value for OS.Therefore,we performed this meta-analysis to assess the associations of ECOG performance status and Gleason score with OS in CRPC patients and compare the two markers in patients under different treatment regimens or with different chemotherapy histories.A systematic literature review of monotherapy studies in CRPC patients was conducted in the PubMed database until May 2019.The data from 8247 patients in 34 studies,including clinical trials and real-world data,were included in our meta-analysis.Of these,twenty studies reported multivariate results and were included in our main analysis.CRPC patients with higher ECOG performance statuses(≥2)had a significantly increased mortality risk than those with lower ECOG performance statuses(<2),hazard ratio(HR):2.10,95%confidence interval(CI):1.68-2.62,and P<0.001.The synthesized HR of OS stratified by Gleason score was 1.01,with a 95%CI of 0.62-1.67(Gleason score≥8 vs<8).Subgroup analysis showed that there was no significant difference in pooled HRs for patients administered taxane chemotherapy(docetaxel and cabazitaxel)and androgen-targeting therapy(abiraterone acetate and enzalutamide)or for patients with different chemotherapy histories.ECOG performance status was identified as a significant prognostic factor in CRPC patients,while Gleason score showed a weak prognostic value for OS based on the available data in our meta-analysis.
文摘We aimed to compare Gleason score and tumor laterality between transrectal ultrasound-guided biopsy of the prostate （TRUSBX） and radical prostatectomy （RP）. Some factors that could cause a discrepancy in results between these two procedures were also evaluated. Among the 318 cases reviewed, 191 cases were selected for inclusion in this comparative Study, We divided the patients into two groups using the Gleason score： an intermediate/high-grade group （≥7） and a low-grade group （〈6）. Exploratory analyses were conducted for comparisons between groups. We also performed comparisons between TRUSBX and RP for tumor laterality. TRUSBX overestimated 6% and underestimated 24% cases in comparison with RP for Gleason score, and overestimated 2.6% and underestimated 46% cases compared with RP for tumor laterality. Biopsy specimens were slightly smaller in TRUSBX cases with underestimated tumor laterality （P〈 0.05）, and no relationship between the biopsy specimen size and underestimated Gleason score in TRUSBX was found. Prostatic volume showed no statistical correlation with the likelihood of under or overestimation （P 〉 0.05）. Thus, our study showed that TRUSBX has a high likelihood of underestimating both the Gleason score and tumor laterality in prostate cancer （PCa）. The size of the fragment appears to be an important factor influencing the likelihood of laterality underestimation and Gleason score overestimation via TRUSBX. Due to the high likelihood of underestimation of the Gleason score and tumor laterality by 12-core prostate biopsy, we conclude that this type of biopsy should not be used alone to guide therapy in Pca.
文摘目的旨在评估动态对比增强磁共振成像(dynamic contrast-enhancement magnetic resonance imaging,DCE-MRI)结合扩散加权成像(diffusion weighted imaging,DWI)在预测前列腺癌(prostate cancer,PCa)Ki-67表达和Gleason评分中的诊断效能。材料与方法回顾性分析了2019年1月至2023年10月自贡市第四人民医院收治的66例PCa患者的临床及影像资料。结合T2WI、DWI序列和由DWI自动计算出的表观扩散系数(apparent diffusion coeffieient,ADC),在DCE-MRI图像上手动勾画肿瘤感兴趣区(region of interest,ROI),计算ROI药代动力学参数,包括容积转运常数(volume transfer contrast,K^(trans))、速率常数(rate contrast,K_(ep))、血管外细胞外容积分数(extravascular extracellular volume fraction,Ve),并测量ADC值。根据靶向穿刺病理诊断Gleason评分和Ki-67表达水平,分为Ki-67高表达组(Ki-67>10%)和低表达组(Ki-67≤10%),Gleason评分低级别(GG 1~2)和高级别(GG 3~5)组。组间差异比较使用两独立样本t检验或非参数检验,采用Spearman相关分析评价DCE-MRI参数和ADC值与Ki-67、Gleason评分的相关性,并建立logistic回归模型,通过受试者工作特征(receiver operating characteristic,ROC)曲线评估诊断效能。结果ADC值与Ki-67表达、Gleason评分均呈负相关(P<0.001),K^(trans)、K_(ep)、Ve与Ki-67表达均呈正相关(P<0.001),K^(trans)、K_(ep)与Gleason评分均呈正相关(P<0.001)。Ki-67高、低表达组K^(trans)、K_(ep)、Ve、ADC值比较差异均具有统计学意义(P<0.01),Gleason评分高、低级别组K^(trans)、K_(ep)、ADC值比较差异均具有统计学意义(P<0.01);Ki-67表达的ROC曲线分析显示,联合模型K^(trans)+K_(ep)+Ve+ADC诊断效能最好,曲线下面积(area under the curve,AUC)为0.940;Gleason评分分级的ROC曲线分析显示,联合模型K^(trans)+K_(ep)+ADC诊断效能最好,AUC为0.861。结论DCE-MRI的药代动力学参数和ADC值相结合,在预测PCa的Ki-67表达和Gleason评分中显示出高诊断效能。联合使用DCE-MRI定量参数与ADC值可提高PCa病理分级和生物侵袭性的预测准确性。
文摘目的研究前列腺癌磁共振扩散张量成像(DTI)参数表观扩散系数(ADC)与各向异性分数(FA)与其病理分级(Gleason评分)的关系,评价ADC值与FA值对于前列腺癌病理分级的诊断价值及评价前列腺癌危险度分级的诊断效能。方法采用3.0 T MR对70例经病理证实的前列腺癌患者行DTI检查,b值为0和800 s/mm2。测量前列腺癌的ADC值及FA值,根据病理结果将患者按Gleason评分系统分为高、中、低危三组:Gleason≥8分、Gleason=7分、Gleason≤6分。对三组数据进行单因素方差分析(one-way ANOVA),并进行组间两两比较。采用Pearson相关分析检验前列腺癌ADC值及FA值与Gleason评分的相关性。将前列腺癌Gleason评分≤7与Gleason评分≥8两组之间进行受试者工作特性(ROC)曲线分析,判断低中危组与高危组诊断界值。结果三组前列腺癌区平均ADC值分别为(0.96±0.10)×10-3mm2/s、(0.76±0.15)×10-3mm2/s和(0.62±0.12)×10-3mm2/s,FA值分别为0.39±0.06、0.31±0.09和0.22±0.06;三组ADC值、FA值组间差异均具有统计学意义(P<0.05);ADC值、FA值与Gleason评分之间均呈负相关(ADC值r=-0.768,P<0.05;FA值r=-0.662,P<0.05),两者均随Gleason评分的增高而减小。以ADC=0.68×10-3mm2/s为临界点,区分低中危组与高危组癌灶的诊断敏感性84.2%,特异性76.9%,准确性87.1%;以FA=0.24为临界点,区分低中危组与高危组癌灶的诊断敏感性79.5%,特异性75.8%,准确性78.4%。结论前列腺癌ADC值及FA值与病理分级(Gleason评分)之间呈负相关,具有预测癌灶恶性程度的潜力,有助于预测前列腺癌的恶性程度。
